Precigen is trading 26.87% lower at $4.92 after FDA approval of Inovio’s VOCERYQ introduced a competing treatment for recurrent respiratory papillomatosis. - The October 30 approval creates competition for PAPZIMEOS, Precigen’s treatment for the same rare disease, after it had been the sole approved treatment. - VOCERYQ received accelerated approval; Inovio must verify clinical benefit in a confirmatory study. - News coverage directly linked the sharp decline to the rival approval, while broader markets were higher.